Table of Content

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenge


5. Global Cystic Fibrosis Therapeutics Market


6. Market Share – Global Cystic Fibrosis Therapeutics

6.1 By Drugs Type
6.2 By Route of Administration
6.3 By Distribution Channel
6.4 By Countries


7. Drug Class – Global Cystic Fibrosis Therapeutics Market

7.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
7.2 Bronchodilators
7.3 Mucolytic
7.4 Pancreatic Enzyme Supplement
7.5 Others


8. Route of Administration – Global Cystic Fibrosis Therapeutics Market

8.1 Oral Drugs
8.2 Inhaled Drugs


9. Distribution Channel – Global Cystic Fibrosis Therapeutics Market

9.1 Hospitals
9.2 Retail Pharmacies
9.3 Others


10. Countries – Global Cystic Fibrosis Therapeutics Market

10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherland
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Forces Analysis – Global Cystic Fibrosis Therapeutics Market

11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis – Global Cystic Fibrosis Therapeutics Market

12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Cystic Fibrosis Drugs Insights

13.1 Marketed Drugs

13.1.1 TRIKAFTA: Vertex Pharmaceuticals

13.1.1.1 Product description
13.1.1.2 Clinical trial & development
13.1.1.3 Safety and efficacy

13.1.2 SYMDEKO: Vertex Pharmaceuticals

13.1.2.1 Product description
13.1.2.2 Clinical trial & development
13.1.2.3 Safety and efficacy

13.1.3 ORKAMBI: Vertex Pharmaceuticals

13.1.3.1 Product description
13.1.3.2 Clinical trial & development
13.1.3.3 Safety and efficacy

13.1.4 KALYDECO: Vertex Pharmaceuticals

13.1.4.1 Product description
13.1.4.2 Clinical trial & development
13.1.4.3 Safety and efficacy

13.2 Emerging Drugs

13.2.1 Ensifentrine: Verona Pharmaceuticals

13.2.1.1 Product description
13.2.1.2 Clinical trial & development
13.2.1.3 Safety and Efficacy

13.2.2 ELX-02: Eloxx Pharmaceuticals, Inc.

13.2.2.1 Product description
13.2.2.2 Clinical trial & development
13.2.2.3 Safety and Efficacy

13.2.3 VX-121/TEZ/ VX-561: Vertex Pharmaceuticals

13.2.3.1 Product description
13.2.3.2 Clinical trial & development
13.2.3.3 Safety and Efficacy

13.2.4 POL6014 (Lonodelestat): Santhera Pharmaceuticals

13.2.4.1 Product description
13.2.4.2 Clinical trial & development
13.2.4.3 Safety and Efficacy

13.2.5 LAU-7b: Laurent Pharmaceuticals Inc.

13.2.5.1 Product description
13.2.5.2 Clinical trial & development
13.2.5.3 Safety and Efficacy


14. Key Players Analysis

14.1 Vertex Pharmaceuticals

14.1.1 Business overview
14.1.2 Key Persons
14.1.3 Recent Development
14.1.4 SWOT Analysis
14.1.5 Revenue Analysis

14.2 Abbvie Inc.

14.2.1 Business overview
14.2.2 Key Persons
14.2.3 Recent Development& Strategies
14.2.4 SWOT Analysis
14.2.5 Revenue Analysis

14.3 Novartis Ag

14.3.1 Business overview
14.3.2 Key Persons
14.3.3 Recent Development
14.3.4 SWOT Analysis
14.3.5 Revenue Analysis

14.4 Gilead Sciences

14.4.1 Business overview
14.4.2 Key Persons
14.4.3 Recent Development
14.4.4 SWOT Analysis
14.4.5 Revenue Analysis

14.5 Viatris INC

14.5.1 Business overview
14.5.2 Key Persons
14.5.3 Recent Development
14.5.4 SWOT Analysis
14.5.5 Revenue Analysis

14.6 Pfizer

14.6.1 Business overview
14.6.2 Key Persons
14.6.3 Recent Development
14.6.4 SWOT Analysis
14.6.5 Revenue Analysis

14.7 Astrazeneca

14.7.1 Business overview
14.7.2 Key Persons
14.7.3 Recent Development
14.7.4 SWOT Analysis
14.7.5 Revenue Analysis

14.8 F. Hoffmann-La Roche Ltd

14.8.1 Business overview
14.8.2 Key Persons
14.8.3 Recent Development
14.8.4 SWOT Analysis
14.8.5 Revenue Analysis